SINOVAC Biotech Ltd. is supplying 101,000 doses of the inactivated COVID-19 vaccine (CoronaVac®), to Singapore. The doses will be available through healthcare group Livingstone Health Holding Limited (SGX: PRH) (“Livingstone Health”).

From 24th September 2021, the vaccines will be available at four clinics under Livingstone Health’s primary healthcare arm Phoenix Medical as well as at Ardennes Health Screening and Radiology Centre. 

Singapore’s Ministry of Health had earlier procured 200,000 doses of the vaccine, of which 170,000 were made available to the public at primary care clinics under the Special Access Route framework. The restocking will reach Singapore on 20^th Sept 2021.

The latest data on CoronaVac®, released in September 2021, indicate that a booster dose of the vaccine can elicit fast and long lasting humoral immune response and effectively neutralise against the Delta variant. Real-world evidence from Chile published in July also showed that CoronaVac® is safe and offers effective protection against COVID-19.

The study was conducted by the Chile Ministry of Health found that CoronaVac® was 65.9% effective at preventing COVID-19 and 87.5% effective at preventing hospitalisation. Additionally, the vaccine was 90.3% effective at preventing Intensive Care Unit (ICU) admission and 86.3% effective at preventing COVID-19 related death.

By the end of August 2021, CoronaVac® had been approved for emergency use by local drug regulatory authorities in nearly 50 countries and regions, including Singapore. The total supply has already exceeded 1.8 billion doses, with an estimated 1.4 billion doses already administrated worldwide. SINOVAC has become the largest domestic supplier and exporter of China’s COVID-19 vaccine. The safety and effectiveness of CoronaVac® has been verified around the world.